Table 1. Comparison of NOACs.
| Author | Study design | Region | Enrollment period | Cohort size | Endpoints | NOACs analyzed |
|---|---|---|---|---|---|---|
| Laliberté et al.30) | RC | US | May 2011 to Jul 2012 | 30,479 | Effectiveness and bleeding | R vs. D |
| Bouillon et al.31) | RC | France | Jan 2011 to Nov 2012 | 17,410 | Effectiveness and bleeding | D, R, or W |
| Abraham et al.32) | RC | US | Nov 2010 to Sep 2013 | 219,027 | GI bleeding | D, R, or W |
| Maura et al.33) | RC | France | Jul to Nov 2012 | 32,807 | Effectiveness and bleeding | D, R, or W |
| Graham et al.17) | RC | US | Nov 2011 to Jun 2014 | 118,891 | Stroke, bleeding, and mortality | R vs. D |
| Noseworthy et al.11) | RC | US | Oct 2010 to Feb 2015 | 31,574 | Effectiveness and bleeding | D, R, or W |
| Deitelzweig et al.34) | RC | US | Jan 2012 to Mar 2014 | 74,730 | Bleeding-related hospital readmissions | D, R, or W |
| Coleman et al.35) | RC | US | Jan 2012 to Oct 2014 | 38,831 | Stroke, ICH | A, R, or W |
| Lip et al.36) | RC | US | Jan 2012 to Dec 2013 | 29,338 | Bleeding | A, D, R, or W |
| Halvorsen et al.37) | Registry | Norway | Jan 2013 to Jun 2015 | 32,675 | Bleeding | A, D, R, or W |
| Chan et al.15) | RC | Taiwan | Feb 2013 to Dec 2013 | 304,252 | Effectiveness and bleeding | D, R, or W |
| Larsen et al.12) | RC | Denmark | Aug 2011 to Oct 2015 | 61,678 | Effectiveness and bleeding | A, D, R, or W |
| Yao et al.38) | RC | US | Oct 2010 to Jun 2015 | 125,243 | Effectiveness and bleeding | A, D, R, or W |
| Lip et al.39) | RC | US | Jan 2012 to Dec 2014 | 33,262 | Major bleeding | A, D, R, or W |
| Gorst-Rasmussen et al.16) | Registry | Denmark | Feb 2012 to Jul 2014 | 22,358 | Effectiveness and bleeding | D, R, or W |
| Staerk et al.13) | Registry | Denmark | Aug 2011 to Dec 2015 | 54,312 | Effectiveness and ICH | A, D, R, or W |
| Lamberts et al.22) | Registry | Denmark | Aug 2011 to Dec 2015 | 54,312 | Bleeding and non-persistence | A, D, R, or W |
| Hohnloser et al.40) | Registry | Germany | Jan 2013 to Mar 2015 | 35,013 | Bleeding | A, D, R, or W |
| Hernandez and Zhang18) | RC | US | Nov 2011 to Dec 2013 | 17,507 | Effectiveness and bleeding | R vs. D |
A = apixaban; D = dabigatran; GI = gastrointestinal; ICH = intracranial hemorrhage; NOAC = non-vitamin K antagonist oral anticoagulant; R = rivaroxaban; RC = retrospective cohort; W = warfarin.